-
Publisher Of
-
DUAL-SPECIFIC IMMUNOTOXIN, D2C7 (SCDSFV)-PE38KDEL, FOR BRAIN TUMOR TREATMENT.
Neuro Oncology.
11:223-223.
2009
-
EGF RECEPTOR TYROSINE KINASE MEDIATES A NOVEL PATHWAY OF DRUG RESISTANCE IN MALIGNANT GLIOMAS VIA TYROSINE PHOSPHORYLATION AND FUNCTIONAL ACTIVATION OF GLUTATHIONE S-TRANSFERASE P1.
Neuro Oncology.
11:218-218.
2009
-
INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII-POSITIVE GBM.
Neuro Oncology.
11:224-224.
2009
-
OTX2 IS ONCOGENIC AND PREDICTS DECREASED SURVIVAL IN MEDULLOBLASTOMA PATIENTS.
Neuro Oncology.
11:234-234.
2009
-
PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.
Neuro Oncology.
11:231-231.
2009
-
RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY.
Neuro Oncology.
11:224-224.
2009
-
THE RNA-BINDING PROTEIN 76 CONTROLS GENE EXPRESSION IN GBM.
Neuro Oncology.
11:221-221.
2009
-
Prevalence of diabetes mellitus in adult patients with primary gliomas on steroid therapy.
Neuro Oncology.
9:567-568.
2007
-
THE MONOMIAL-DIVISOR MIRROR MAP.
Duke Mathematical Journal.
72:319-337.
1993
-
A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB.
Neuro Oncology.
656-656.
2009
-
CTLA-4 BLOCKADE AUGMENTS VACCINE-INDUCED ANTITUMOR IMMUNITY AGAINST INTRACRANIAL GLIOMA.
Neuro Oncology.
618-618.
2009
-
Developmental and functional outcome following postoperative chemotherapy and local conformal radiation in infants with medulloblastoma using a centrally administered phone-based interview technique, initial report: A children's oncology group study.
Neuro Oncology.
434-434.
2008
-
Dual-specific antibody, D2C7 (SCDSFV)-PE38KDEL for brain tumor therapy.
Neuro Oncology.
379-379.
2008
-
Establishment and characterization of cell lines and transplantable xenografts from pediatric brain tumors.
Neuro Oncology.
380-380.
2008
-
Ganglioside expression in pediatric brain tumor xenograft lines.
Neuro Oncology.
381-382.
2008
-
Identification of antigens on cancer stem cells for brain tumor therapy.
Neuro Oncology.
384-384.
2008
-
In vivo bioluminescence imaging of luciferase-expressing pediatric brain tumor xenografts in rodent models.
Neuro Oncology.
509-509.
2008
-
The oncogenic role of OTX2 in medulloblastoma pathogenesis and its clinical implications as a tumor marker and therapeutic target.
Neuro Oncology.
390-390.
2008
-
Characterization of brain tumor exosomes: Biology, biochemistry, immumology.
Neuro Oncology.
501-501.
2007
-
Deregulation of an extraordinarily important developmental gene promotes medulloblastoma tumorigenesis.
Neuro Oncology.
555-555.
2007
-
Efficacy of dronabinol for nausea, vomiting, and appetite disturbances in adult patients with primary malignant gliomas.
Neuro Oncology.
567-567.
2007
-
Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11).
Neuro Oncology.
573-574.
2007
-
In vivo characterization of the blood-brain and blood-tumor barrier in orthotopic xenograft tumors derived from adult and pediatric malignant gliomas.
Neuro Oncology.
486-487.
2007
-
Phase II trial of Zoledronic Acid (ZA) for bone loss prevention in glioma patients.
Neuro Oncology.
566-566.
2007
-
RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma.
Neuro Oncology.
509-509.
2007
-
Rhabdomyosarcoma (RMS) of extremity and cerebral glioblastoma multiforme (GBM) in a child with Li-fraumeni syndrome and germline TP53 splice mutation.
Neuro Oncology.
544-544.
2007
-
Stat3 constitutive activation is associated with glioma tumor grade: Pathway profiling and therapy.
Neuro Oncology.
550-550.
2007
-
Targeting constitutively activated stat3 sensitizes medulloblastomas to chemotherapeutic agents.
Neuro Oncology.
560-560.
2007
-
Targeting hedgehog signaling in medulloblastoma.
Neuro Oncology.
560-561.
2007
-
Temozolomide therapy induces an increase in regulatory T-cells without abbrogating a specific tumor.
Neuro Oncology.
509-509.
2007
-
Phase I trial of oral temozolomide and intravenous O-6-benzylguanine (O-6-BG), a methylguanine methyltransferase inhibitor, in pediatric patients with recurrent brain tumors.
Neuro Oncology.
189-189.
2007
-
Pilot phase II study of metrenomic oral cyclophosphamide plus thalidomide in children with recurrent malignant brain tumors.
Neuro Oncology.
203-203.
2007
-
Risk of stroke among long-term survivors of childhood brain tumors: A report from the childhood cancer survivor study.
Neuro Oncology.
170-171.
2007
-
A novel low-molecular-weight inhibitor of focal adhesion kinase, inhibits glioma growth.
Neuro Oncology.
417-417.
2006
-
A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma.
Neuro Oncology.
441-441.
2006
-
AAL881, a novel small molecule inhibitor of RAF and VEGFR activities, blocks growth of malignant glioma.
Neuro Oncology.
417-417.
2006
-
Bevacizumab and irinotecan is an effective treatment for malignant gliomas.
Neuro Oncology.
454-454.
2006
-
Characterizing genomic rearrangements in oligodendroglioma using whole genome tilepath hrCGH arrays.
Neuro Oncology.
421-421.
2006
-
Development of the duke cancer cognitions inventory-brain tumor version (DCCI-BT).
Neuro Oncology.
476-476.
2006
-
Exposure assessment methodology in a brain cancer epidemiology study.
Neuro Oncology.
406-406.
2006
-
Fatigue in adolescent survivors of pediatric cancer.
Neuro Oncology.
476-476.
2006
-
Glioma cancer stem cells promote tumor angiogenesis through vascular endothelial growth factor.
Neuro Oncology.
392-392.
2006
-
Glutathione S-transferase P1 (GSTP1) is a novel downstream target of Akt in human gliomas.
Neuro Oncology.
400-400.
2006
-
Hydrocephalus as an additional risk factor for academic and intellectual outcome in survivors of pediatric medulloblastoma treated with radiation.
Neuro Oncology.
479-480.
2006
-
Neurocognitive deficits according to hemisphere and diagnosis among patients with high-grade CNS tumors.
Neuro Oncology.
476-477.
2006
-
Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy.
Neuro Oncology.
437-437.
2006
-
Parent and family psychosocial adjustment as a function of pediatric tumor type.
Neuro Oncology.
479-479.
2006
-
Patient-specific murine I-131-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study.
Neuro Oncology.
489-489.
2006
-
Phase I trial of Temodar plus O-6-benzylguanine 5-day regimen for patients with progressive glioblastoma multiforme.
Neuro Oncology.
450-450.
2006
-
Phase I trial of temozolomide plus dose-escalating imatinib mesylate for patients with malignant glioma.
Neuro Oncology.
451-451.
2006
-
Polymorphism of the promoter of the epidermal growth factor (EGF) gene in patients, its distribution and correlation with survival in glioma patients.
Neuro Oncology.
420-420.
2006
-
Secreted protein acidic and rich in cysteine (SPARC) induces glioma invasion and survival through activation of focal adhesion kinase and integrin-linked kinase.
Neuro Oncology.
401-401.
2006
-
The combination of novel low-molecular-weight inhibitors of Raf (LBT 613) and TOR (RAD001, everolimus) decreases glioma proliferation and invasion.
Neuro Oncology.
412-412.
2006
-
A novel mechanism of PKA- and PKC-dependent drug resistance in human gliomas involving phosphorylation and metabolic activation of glutathione S-transferase P1 (GSTP1).
Neuro Oncology.
377-377.
2005
-
An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity.
Neuro Oncology.
311-311.
2005
-
Comination of imatinib mesylate (STI-571, Gleevec) and temozolomide (temodar) displays increased activity against glioma xenografts.
Neuro Oncology.
387-387.
2005
-
Enhanced cellular retention of an internalizing anti-EGFRvIII monoclonal antibody radioiodinated using LYS5-[*I]iodobenzoyl Gly(1)-maleimido GEEEK ([*I]IB-Mal-D-GEEEK), a prosthetic group containing negatively charged D-glutamates.
Neuro Oncology.
386-386.
2005
-
Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model.
Neuro Oncology.
301-301.
2005
-
GPNMB: A new target for human high-grade gliomas (HGL) immunotherapy.
Neuro Oncology.
369-369.
2005
-
Gene expression profiling links invasion-related genes to poor survival in older glioblastoma patients.
Neuro Oncology.
293-293.
2005
-
Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results.
Neuro Oncology.
291-291.
2005
-
Immunologic targeting of the tumor-specific antigen contained in the deletion mutation of the epidermal growth factor receptor (EGFRvIII) with peptide loaded dendritic cells in patients with malignant gliomas.
Neuro Oncology.
350-350.
2005
-
Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status.
Neuro Oncology.
343-344.
2005
-
PIK3CA is mutated in oligodendrogliomas, astrocytomas, and medulloblastomas and associated with chromosome 1p, 19q LOH in oligodendrogliomas.
Neuro Oncology.
345-345.
2005
-
Phase I study results of Gefitinib (iressa; ZD1839) plus rapamycin in the treatment of patients with recurrent malignant glioma.
Neuro Oncology.
312-312.
2005
-
Phase II study of cloretazine for the treatment of adults with recurrent malignant glioma.
Neuro Oncology.
317-317.
2005
-
Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas.
Neuro Oncology.
370-370.
2005
-
Prevalence and prognostic significance of polymorphisms at the glutathione S-transferase M1, M3, P1, and T1 gene loci in human astrocytomas.
Neuro Oncology.
304-304.
2005
-
Quality of life in pediatric brain tumor survivors.
Neuro Oncology.
336-336.
2005
-
Targeting malignant gliomas with a low-molecular-weight Raf/vascular endothelial growth factor receptor inhibitor.
Neuro Oncology.
379-379.
2005
-
Temozolomide (TMZ) with O6-benzylguanine (BG) for TMZ-resistant malignant glioma: A phase 2 trial.
Neuro Oncology.
401-401.
2005
-
Temozolomide (TMZ) with O6-benzylguanine (BG) plus CPT-11 in the treatment of recurrent malignant glioma: A phase I trial.
Neuro Oncology.
320-320.
2005
-
The PTEN tumor suppressor gene shifts cellular responses to transforming growth factor-beta towards tumor suppression in malignant gliomas.
Neuro Oncology.
298-298.
2005
-
VEGF cooperates with secreted protein acidic and rich in cysteine (SPARC) to activate intracellular glioma survival pathways.
Neuro Oncology.
286-286.
2005
-
Convection-enhanced delivery of IL13-PE38QQR in malignant glioma: Comparison of observed and predicted drug distribution.
Neuro Oncology.
381-382.
2004
-
Dendritic cell vaccine for intracranial tumors I (DC Victori trial).
Neuro Oncology.
341-341.
2004
-
Detection and immunologic recognition of cytomegalovirus antigens expressed within malignant gliomas.
Neuro Oncology.
343-343.
2004
-
Evaluating impact of symptom management on quality of life in glioma patients.
Neuro Oncology.
355-355.
2004
-
Extraosseous Ewings sarcoma (EES) of the central nervous system (CNS) - Case reports and molecular diagnosis.
Neuro Oncology.
457-457.
2004
-
Immunotherapeutic target antigen phenotypes of pediatric vs. adult central nervous system (CNS) tumor biopsies, xenografts, and cultured cells.
Neuro Oncology.
415-416.
2004
-
Incidence and patterns of neuraxis metastasis (NM) in patients (PTS) with diffuse pon'ine glioma (DPG).
Neuro Oncology.
417-417.
2004
-
Inhibition of receptor tyrosine kinases and mammalian target of rapamycin offers combinatorial benefit in tumor control.
Neuro Oncology.
407-407.
2004
-
Medulloblastoma neoplastic meningitis targeted radiotherapy with intrathecal alpha-emitter At-211-labeled thymidine analogue.
Neuro Oncology.
403-403.
2004
-
Molecular genomics of medulloblastoma.
Neuro Oncology.
416-416.
2004
-
Monoclonal antibodies (MABS) against somatostatin receptor 2A (SSTR2A) as potential medulloblastoma therapeutic reagents.
Neuro Oncology.
409-409.
2004
-
Phase I trial of adults with primary malignant glioma with irinotecan (CPT-11) plus temozolomide (Temodar).
Neuro Oncology.
373-374.
2004
-
Phase I trial of temozolomide (Temodar) plus irinotecan (CPT-11) plus O6-benzylguanine (O6-BG) in the treatment of recurrent or progressive cerebral anaplastic gliomas.
Neuro Oncology.
380-380.
2004
-
Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors.
Neuro Oncology.
381-381.
2004
-
Phase II study of oral temozolomide (TMZ) in children with progressive low-grade gliomas (LGG).
Neuro Oncology.
457-457.
2004
-
Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma.
Neuro Oncology.
381-381.
2004
-
Phase II trial of temozolomide (Temodar) plus O6-benzylguanine (O6-BG) in the treatment of patients with Temodar-resistant malignant glioma.
Neuro Oncology.
380-380.
2004
-
Phase II upfront CPT-11 plus celecoxib for adults with glioblastoma multiforme.
Neuro Oncology.
369-370.
2004
-
Preliminary evidence of nonverbal learning disability in survivors of pediatric brain tumors.
Neuro Oncology.
446-446.
2004
-
SB-431542, a small molecule transforming growth factor-B-receptor antagonist, inhibits human glioma cell line proliferation and motility.
Neuro Oncology.
408-408.
2004
-
Somatostatin targeted radiotherapeuiccs for medulloblastoma.
Neuro Oncology.
416-416.
2004
-
Theoretical estimation of dermal exposure to known and suspected animal neurocarcinogens.
Neuro Oncology.
326-327.
2004
-
ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.
Neuro Oncology.
413-413.
2004
-
Microfoundations Reconsidered: The Relationship of Micro and Macroeconomics in Historical Perspective.
History of Political Economy.
352-356.
2014
-
The Microfoundations Delusion: Metaphor and Dogma in the History of Macroeconomics.
History of Political Economy.
352-356.
2014